Skip to contentpdufa.bio

IGALMI (dexmedetomidine hydrochloride): FDA NDA 215390

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 215390 is the FDA application for IGALMI (dexmedetomidine hydrochloride). The FDA's Orange Book lists the applicant of record as TEVA NEUROSCIENCE INC and the first approval on it as Apr 5, 2022. Code name used in development: BXCL501. Owner today: Teva Pharmaceutical Industries Ltd. (NYSE/TASE: TEVA).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 215390 · Orange Book NDA 215390

Names for this drug

Brand name (FDA)IGALMI
Orange Book trade name: IGALMI
Active ingredient (FDA)DEXMEDETOMIDINE HYDROCHLORIDE
Code nameBXCL501
Source: BioXcel Therapeutics 10-K, Mar 27, 2026
“BXCL501 (currently marketed and commercialized as IGALMI)”

Who holds the application

FDA applicant of recordTEVA NEUROSCIENCE INC
FDA Orange Book data files as of Nov 13, 2026
Owner todayTeva Pharmaceutical Industries Ltd. (TEVA)
Source: Teva press release, Nov 16, 2026
“a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)” … “Teva acquired IGALMI in late October 2026.”
Earlier / partnerBioXcel Therapeutics (ticker at the time: BTAI): sold the product to the current owner, Oct 26, 2026
Source: BioXcel Therapeutics 8-K, Oct 30, 2026
“On October 26, 2026, the Debtors completed the Sale, pursuant to which Teva acquired” … “BTAI”

Products on NDA 215390 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001IGALMIFILM;BUCCAL, SUBLINGUALEQ 0.12MG BASEApr 5, 2022
002IGALMIFILM;BUCCAL, SUBLINGUALEQ 0.18MG BASEApr 5, 2022

FDA decisions we track for this drug

IGALMI (dexmedetomidine sublingual film) - (SERENITY At-Home)TEVA · Decided

Drug page: /drug/igalmi

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.